Biodesix Inc (BDSX) News

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release...

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Studies highlight advancements in technology to detect cell-free DNA and rapid turnaround time in a real-world clinical setting Biodesix, Inc...

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its...

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief...

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release...

Form 4 - Statement of changes in beneficial ownership of securities